|1.||Sebti, Said: 2 articles (09/2015 - 10/2007)|
|2.||Malafa, Mokenge: 2 articles (09/2015 - 10/2007)|
|3.||Li, Shau-Hsuan: 2 articles (04/2014 - 09/2012)|
|4.||Ge, Hailiang: 2 articles (04/2014 - 09/2012)|
|5.||Wang, Qingfei: 2 articles (04/2014 - 09/2012)|
|6.||Li, Ping: 2 articles (04/2014 - 09/2012)|
|7.||Hortobagyi, Gabriel N: 2 articles (09/2012 - 10/2007)|
|8.||Yu, Dihua: 2 articles (09/2012 - 10/2007)|
|9.||Cheng, Jin Q: 2 articles (05/2011 - 10/2007)|
|10.||Coppola, Domenico: 2 articles (05/2011 - 10/2007)|
|1.||Pulmonary Fibrosis (Hamman Rich Syndrome)
08/01/2015 - "The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis."
08/01/2015 - "We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. "
04/01/2014 - "Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors."
01/01/2014 - "Triciribine hydrate (TCN), the inhibitor of Akt, decreased the gastric tumor weight and size in the nude mice and abolished REG4-induced weight and size increase of the tumor. "
03/01/2012 - "Also we investigated triciribine's induction of apoptosis and effects on a broad range of cancer-associated gene products. "
01/01/2013 - "A promising combination, dasatinib and triciribine, was explored in a murine model using the A673 cell line, and tumors were evaluated by MRI and histology for therapy effect. "
01/01/2013 - "Importantly, in nude mice inoculated with HCC Huh7 cells, we demonstrated a synergistic inhibitory effect of the PPARγ agonist rosiglitazone and the AKT inhibitor triciribine on tumor growth. "
|5.||Breast Neoplasms (Breast Cancer)
07/01/2012 - "This study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. "
07/01/2012 - "Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. "
07/01/2012 - "Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217."
05/01/2011 - "In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. "
10/01/2007 - "When trastuzumab was combined with the Akt inhibitor triciribine, breast cancer cell growth was inhibited and apoptosis was induced. "
|1.||2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidine
|2.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|4.||Biological Markers (Surrogate Marker)
|6.||Protein Kinases (Protein Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)